prostate cancer

Research in Review

Palliative Drugs In Combination With Docetaxel Can Improve Prostate Cancer Care

02/23/2016

JCP Editors

A clinical trial has shown that combining the chemotherapy drug docetaxel with other treatments can improve clinical outcomes in patients with bony metastatic castrate-refractory prostate cancer (CRPC). The...

A...

02/23/2016

Journal of Clinical Pathways

Clinical Insights

Prostatic Artery Embolization for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: Articles From the Official Show Daily for Synergy 2015

02/15/2016

Francisco Cesar Carnevale, MD, PhD; Shivank Bhatia, MD

From the Interventional Radiology Section, University of Sao Paulo Medical School, Sao Paulo, Brazil, and the University of Miami Miller School of Medicine, Miami, Florida, USA.

Francisco Cesar Carnevale, MD, PhD; S...

The standard management of benign prostatic obstruction (BPO) is based on the overall health of the patient, on the severity of the lower urinary tract symptoms (LUTS), and on quality-of-life considerations. Voiding difficulties attributable...

The standard management of...

02/15/2016

IO Learning

Research in Review

Enzalutamide Improves Survival Over Bicalutamide in Castration-Resistant Prostate Cancer

02/02/2016

JCP Editors

Treatment with enzalutamide rather than bicalutamide for nonmetastatic or metastatic castration-resistant prostate cancer (CRPC) improves survival, according to results of a phase 2 clinical trial. CRPC occurs when...

...

02/02/2016

Journal of Clinical Pathways

Research in Review

Bankruptcy Associated with Increased Mortality Risk for Patients with Cancer

01/29/2016

JCP Editors

A new study suggests that financial stress, rooted in filing for bankruptcy, may be a risk factor for increased mortality after a cancer diagnosis. Patients with cancer are more likely than the general population to...

A new...

01/29/2016

Journal of Clinical Pathways

Conference Coverage

2016 Genitourinary Cancers Symposium

01/28/2016

JCP Editors

The American Society of Clinical Oncology’s 2016 Genitourinary Cancers Symposium was held earlier this month (January 7-9) in San Francisco, California, where the brightest professionals in urology, oncology, and...

The...

01/28/2016

Journal of Clinical Pathways

Research in Review

Earlier Chemotherapy Improves Outcomes for Patients With Prostate Cancer

12/30/2015

JCP Editors

Results from a recent clinical trial have shown that earlier chemotherapy treatment may lead to improved outcomes for prostate cancer patients initiating long-term hormone therapy. A paper published in Lancet...

...

12/30/2015

Journal of Clinical Pathways

News

FDA Fully Approves Non-Invasive HIFU Treatment for Prostate Cancer

12/03/2015

TORONTO, Dec. 3, 2015 /PRNewswire/ -- The FDA has fully approved the non-surgical, non-invasive treatment for prostate cancer known as HIFU or High Intensity Focused Ultrasound Therapy.  The Food and Drug Administration approved HIFU...

TORONTO, Dec. 3, 2015...

12/03/2015

IO Learning

Interview

Focus on Treatment of Prostate Disease During Opening of 5th-Anniversary Interventional Oncology Meeting

11/06/2015

By Jennifer FordOn November 5, 2015, the Synergy 2015 meeting had a successful start, celebrating 5 years of a multidisciplinary approach to interventional cancer care. The meeting welcomed nearly 500 registrants to Miami for this year’s...

By Jennifer FordOn November 5,...

11/06/2015

IO Learning

News

FDA Approves First Focused Ultrasound System for Treating the Prostate

10/13/2015

Newswise — Charlottesville, Virginia, October 13, 2015 -- The US Food and Drug Administration has approved SonaCare Medical’s Sonablate 450 focused ultrasound system for the ablation of prostate tissue. Focused ultrasound enables...

Newswise — Charlottesville,...

10/13/2015

IO Learning

News

Philips and Profound Medical Collaborate to Support Transurethral Ultrasound Ablation for Prostate Cancer

07/21/2015

July 21, 2015 07:15 AM Eastern Daylight TimeBEST, Netherlands & TORONTO--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX : PHIA) and Profound Medical Corp. (TSXV: PRN), a Toronto-based medical device company, today announced that they have...

July 21, 2015 07:15 AM Eastern...

07/21/2015

IO Learning